Key Takeaways QGEN is expanding key platforms with FDA-cleared panels and new digital PCR assay launches. Strategic deals with Eli Lilly, AstraZeneca, and others are fueling QGEN's diagnostic innovations. QGEN maintains solid solvency, with $638.8M in cash and just $56M in current debt as of Q1 2025.QIAGEN N.V. (QGEN) is well-poised to grow in the upcoming quarters, courtesy of substantial investment in research and development (R&D) for the menu expansion of its key platforms. Expanding through partnersh ...

Qiagen (QGEN) FY Conference June 09, 2025 09:00 AM ET Speaker0 Hi, good morning, everyone. I'm Matt Sykes, Life Science Tools and Diagnostics Analyst at Goldman Sachs. I have the pleasure of being joined by Roland Saker, CFO and John Gallardi, Head of IR. Roland, John, thanks for being here. Speaker1 Thank you. Speaker2 Thank you. Speaker0 Maybe we could start out, just given the current environment we're in, which is continues to be challenging, maybe just talk through sort of the durability of your end ma ...

Qiagen (QGEN) 2025 Conference June 05, 2025 09:55 AM ET Speaker0 Okay. Thanks. Speaker1 I think, Roland, maybe I'll just start off with a higher level question. You've done a lot in terms of reshaping the portfolio. You're buying stock. You've got, you know, expanding margins. You're you're doing all the right things. I think are there areas areas you think you could be doing more and what do you Speaker2 think is Speaker1 most underappreciated right now? Speaker2 First thing that I'm going to do is buy a n ...

QIAGEN N.V. (QGEN) recently entered into a commercial partnership and co-marketing agreement with ID Solutions, a French provider of high-quality digital PCR (dPCR) assays, to expand the availability of dPCR assays for oncology research applications. The latest partnership is likely to expand QIAGEN’s position in oncology-focused digital PCR assays, advancing QIAcuity as the platform of choice for cancer research.QGEN Stock’s Likely Trend Following the NewsFollowing the announcement, shares of QIAGEN remain ...

Qiagen (QGEN) 2025 Conference May 14, 2025 01:00 PM ET Speaker0 On how the quarter played out relative to your expectations, but what were the big surprises? What really stood out to you? Speaker1 No. Again, first of thanks for having us. It's always a pleasure to be here. And well, as you said, Q1 was actually a very strong start for QIAGEN into the year. We clearly came in with a 7% growth rate revenue wise. We were able not only to beat our EPS guidance for the quarter, we also feel quite comfortable to ...

Qiagen (QGEN) Q1 2025 Earnings Call May 08, 2025 09:00 AM ET Company Participants John Gilardi - Vice President & Head of Corporate CommunicationsThierry Bernard - CEO, MD & Member of Management BoardRoland Sackers - CFO, MD & Member of Management BoardDoug Schenkel - Managing DirectorTycho Peterson - Managing DirectorMichael Ryskin - Managing DirectorJan Koch - VP - Equity ResearchDaniel Brennan - Managing DirectorCasey Woodring - Vice President - Equity Research Conference Call Participants Dan Leonard - ...

Qiagen (QGEN) Q1 2025 Earnings Call May 08, 2025 09:00 AM ET Speaker0 Ladies and gentlemen, thank you for standing by. I'm Lisa, your PGI call operator. Welcome, and thank you for joining QIAGEN's Q1 twenty twenty five Earnings Conference Call Webcast. At this time, all participants are in a listen only mode. Please be advised that this call is being recorded at QIAGEN's request and will be made available on their Internet site. The prepared remarks will be followed by a question and answer session. At this ...

QIAGEN N.V.’s (QGEN) first-quarter 2025 adjusted earnings per share (EPS) were 55 cents, and 56 cents at constant exchange rate (CER). The bottom line increased 17% from the year-ago level. Additionally, it surpassed the Zacks Consensus Estimate by 10%.The adjustment excludes the impact of certain non-recurring items, such as business integration, acquisition and restructuring-related expenses, purchased intangible amortization expenses and non-cash interest expense charges, among others.On a GAAP basis, EP ...

Wall Street analysts forecast that Qiagen (QGEN) will report quarterly earnings of $0.50 per share in its upcoming release, pointing to a year-over-year increase of 6.4%. It is anticipated that revenues will amount to $464.04 million, exhibiting an increase of 1.1% compared to the year-ago quarter.The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial project ...